A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients
Status:
RECRUITING
Trial end date:
2026-12-15
Target enrollment:
Participant gender:
Summary
FIH, Phase 1/2, multi-centre, randomised, double-blind, placebo controlled study with an optional open-label dosing extension to assess the safety, tolerability, efficacy, and Pharmacodynamics (PD) of single or multiple (up to 48 weeks QD) subcutaneous (SC) doses of PLL001 compared to placebo in subjects diagnosed with ALS.